Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Suven Life Sciences Ltd

| Q1 FY26 Earnings Conference Call Transcript

NEUTRAL SENTIMENT

Report Source

⬤13th Aug 25

Summary : Cohance Lifesciences reported Q1 FY'26 revenue growth driven by specialty and API segments, with strong CDMO demand, despite inventory destocking, while reiterating its $1 billion 2030 revenue target.

Management Perspective positive : Q1 FY '26 has been an important start to the year, strengthening our foundation.Pleased to share the transition is on track, with increasing alignment.We remain confident of delivering full-year growth targets.We reiterate our FY'26 guidance and $1 billion target by 2030.I am very excited, I think, with the teams that we have.

Concall Report Analysis & Insights

Business Overview

  1. Cohance Lifesciences operates as a technology-led global CDMO.
  2. The company has a 3-pillar structure: Pharma CDMO, Specialty Chemicals, and API Plus.
  3. Q1 FY'26 marks the first full quarter operating as a unified Cohance platform.
  4. The company focuses on scientific partnership, speed, and reliability.
  5. Niche technology revenue share rose from mid-teens in FY'25 to over 20% in Q1 FY'26.

Future Growth Prospects

  1. Expanding offerings into next-generation modalities like pegylated antibody conjugates.
  2. Oligonucleotide building block facility at Nacharam expected to be fully operational by CY '25.
  3. Two small molecule products are expected to commercialize in 12-18 months.
  4. Secured a lifecycle management supply mandate for a branded API.
  5. Targeting $1 billion revenue by 2030 with mid-30s EBITDA margins.

Management Insights

  1. Q1 FY'26 performance is in-line with expectations and outlined trajectory.
  2. Pharma CDMO segment grew over 30% year-over-year, excluding inventory de-stocking.
  3. Strong demand across key customer programs in high-value modalities.
  4. Invested INR 559 million in CAPEX for capacity expansion and debottling.
  5. Reaffirmed FY'26 guidance and long-term target of $1 billion revenue by 2030.

Signs of Skepticism

  1. Analyst questioned if one-time expenses will continue with M&A activity.
  2. Analyst sought clarity on FY'26 organic growth and margin levels.
  3. Analyst asked about the overall market size of a new branded API product.
  4. Analyst questioned the specific reasons for inventory destocking by innovators.
  5. Analyst struggled to get a clear breakdown of the 2030 guidance from current platform capabilities.

Risk Factors

  1. Inventory de-stocking in Pharma CDMO temporarily impacted Q1 FY'26 revenue growth.
  2. One-time expenses related to M&A and talent acquisition affect P&L.
  3. ESOP charges are variable and expected to increase with future grants.
  4. Potential future tariffs on intermediates, though currently exempt from US tariffs.

Good To Know

  1. Formed Cohance External Advisory Board with 5 highly respected industry stalwarts.
  2. Appointed Mr. Yann D'Herve as CEO of the CDMO business.
  3. Dr. Sudhir Singh stepped back from active executive responsibilities.
  4. Secured another USFDA approval for a partner program with priority review.
  5. Engaged with over 19 global innovators, including NJ Bio and Sapala networks.

Key Drivers

  1. New ADC order from existing customer.
  2. Oligonucleotide facility fully operational by CY'25.
  3. Two small molecule products commercializing soon.
  4. Branded API lifecycle management mandate.

Key Analyst Discussions

Competitive Environment

  1. Seeing continued RFQ inflows due to China Plus One and EU Plus One trends.
  2. Positioned as a dependable CDMO partner for innovators seeking supply security.
  3. Deepening engagements with 3 additional large innovator companies.
  4. API+ strategy focuses on lifecycle management for matured molecules.
  5. Dominant market player for a specific branded API with new innovator addition.

Market Trends & Consumer Behavior

  1. Evolving global sourcing strategies drive RFQ inflows for CDMO services.
  2. Growing interest in payload linker synthesis for long-term supply chain strategies.
  3. Expanding into next-generation modalities like pegylated antibody conjugates.
  4. AgChem business shows improving sequential recovery and visibility.
  5. Performance Chemicals shipments expected to ramp up later in the year.

Financial Highlights

  1. Q1 FY'26 revenue grew 13% year-on-year, led by specialty business and API.
  2. Pharma CDMO grew over 30% year-on-year, excluding inventory destocking impact.
  3. Niche technology revenue share rose to over 20% in Q1 FY'26.
  4. Invested INR 559 million in CAPEX for capacity expansion and debottling.
  5. Generated INR 2.3 billion in free cash flow, ending with INR 4.4 billion cash.

Product Composition

  1. Strong performance in API Plus and FDA business with healthy pipeline.
  2. Validated 2 new API products, 7-8 more expected with regulatory filings.
  3. ADC platform gaining momentum across payload and bioconjugation modalities.
  4. Oligonucleotide building block facility progressing on schedule for commercialization.
  5. Small molecule portfolio expects two products to commercialize in 12-18 months.

Strategic Considerations

  1. Investing in front-end capabilities across US, Europe, Japan, Southeast Asia.
  2. Expanding bioconjugation capacity at Princeton facility with $10 million investment.
  3. Final decision on payload selection rests fully with the innovator.
  4. Not currently looking to acquire mAB manufacturing capabilities.
  5. Targeting $1 billion revenue by 2030 with mid-30s EBITDA margins.